Biomarkers of Plaque Instability

Current Cardiology Reports

Volumn 16, Issue 12, 2014, Pages

  Shah, P K ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Atherosclerosis; Biomarker; High risk; Inflammation; Lipid core; Plaque; Vulnerable

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; APOLIPOPROTEIN A1; BIOLOGICAL MARKER; C REACTIVE PROTEIN; FIBRINOGEN; GAMMA INTERFERON; INTERLEUKIN 18; INTERLEUKIN 6; MATRIX METALLOPROTEINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOPEROXIDASE; OXIDIZED LOW DENSITY LIPOPROTEIN; PLACENTAL GROWTH FACTOR; PREGNANCY ASSOCIATED PLASMA PROTEIN A; SECRETORY PHOSPHOLIPASE A2; TRIMETHYLAMINE OXIDE; HUMAN PLATELET ANTIGEN 1B; METHYLAMINE; PAPPA1 PROTEIN, HUMAN; PEROXIDASE; THROMBOCYTE ANTIGEN; TRIMETHYLOXAMINE;

ACUTE CORONARY SYNDROME; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; CORONARY ARTERY OCCLUSION; HUMAN; INFLAMMATION; OXIDATIVE STRESS; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SMOOTH MUSCLE FIBER; BLOOD; CORONARY ARTERY THROMBOSIS; COST BENEFIT ANALYSIS; EXTRACELLULAR MATRIX; METABOLISM; PATHOPHYSIOLOGY;

ANTIGENS, HUMAN PLATELET; APOLIPOPROTEIN A-I; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CORONARY ARTERY DISEASE; CORONARY THROMBOSIS; COST-BENEFIT ANALYSIS; EXTRACELLULAR MATRIX; HUMANS; INFLAMMATION; INTERLEUKIN-18; INTERLEUKIN-6; METHYLAMINES; PEROXIDASE; PLAQUE, ATHEROSCLEROTIC; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A; PROGNOSIS;

EID: 84910663019     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-014-0547-7     Document Type: Review

References (89)

1. Shah PK. Molecular mechanisms of plaque instability. Curr Opin Lipidol. 2007;18(5):492–9. Review.
2. Bentzon JF, Otsuka F, Virmani R, Falk E. Mechanisms of plaque formation and rupture. Circ Res. 2014;114(12):1852–66. An outstanding overview of atherogenesis and mechanisms of plaque rupture.
3. Kolodgie FD, Gold HK, Burke AP, Fowler DR, Kruth HS, Weber DK, et al. Intraplaque hemorrhage and progression of coronary atheroma. N Engl J Med. 2003;349(24):2316–25.
4. Bluestein D, Alemu Y, Avrahami I, Gharib M, Dumont K, Ricotta JJ, et al. Influence of microcalcifications on vulnerable plaque mechanics using FSI modeling. J Biomech. 2008;41(5):1111–8.
5. Garcia-Garcia HM, Jang IK, Serruys PW, Kovacic JC, Narula J, Fayad ZA. Imaging plaques to predict and better manage patients with acute coronary events. Circ Res. 2014;114(12):1904–17.
6. Koenig W, Khuseyinova N. Biomarkers of atherosclerotic plaque instability and rupture. Arterioscler Thromb Vasc Biol. 2007;27(1):15–26.
7. Calabro P, Willerson JT, Yeh ET. Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells. Circulation. 2003;108:1930.
8. Yasojima K, Schwab C, McGeer EG, McGeer PL. Generation of C-reactive protein and complement components in atherosclerotic plaques. Am J Pathol. 2001;158:1039–51.
9. Burke AP, Tracy RP, Kolodgie F, Malcom GT, Zieske A, Kutys R, et al. Elevated C-reactive protein values and atherosclerosis in sudden coronary death: association with different pathologies. Circulation. 2002;105:2019–23.
10. Verma S, Devaraj S, Jialal I. Is C-reactive protein an innocent bystander or proatherogenic culprit? C-reactive protein promotes atherothrombosis. Circulation. 2006;113:2135–50.
11. Wensley F, Gao P, Burgess S, Kaptoge S, Di Angelantonio E, Shah T, et al. Association between C reactive protein and coronary heart disease: C Reactive Protein Coronary Heart Disease Genetics Collaboration (CCGC), mendelian randomisation analysis based on individual participant data. BMJ. 2011;342:d548.
12. Pepys MB, Hawkins PN, Kahan MC, Tennent GA, Gallimore JR, Graham D, et al. Proinflammatory effects of bacterial recombinant human C-reactive protein are caused by contamination with bacterial products, not by C-reactive protein itself. Circ Res. 2005;97:e97–e103.
13. Lane T, Wassef N, Poole S, Mistry Y, Lachmann HJ, Gillmore JD, et al. Infusion of pharmaceutical-grade natural human C-reactive protein is not proinflammatory in healthy adult human volunteers. Circ Res. 2014;114(4):672–6. An important study that fails to support proinflammatory effects of CRP in humans.
14. Emerging Risk Factors Collaboration1, Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet. 2010;375(9709):132–40. doi:10.1016/S0140-6736(09)61717-7.
15. Kaptoge S, Di Angelantonio E, Pennells L, Wood AM, White IR, Gao P, et al. C-reactive protein, fibrinogen, and cardiovascular disease prediction. Emerging Risk Factors Collaboration. N Engl J Med. 2012;367(14):1310–20. An important study evaluating the value of CRP measurement for risk prediction.
16. Rus HG, Vlaicu R, Niculescu F. Interleukin-6 and interleukin-8 protein and gene expression in human arterial atherosclerotic wall. Atherosclerosis. 1996;127:263–71.
17. Lindmark E, Diderholm E, Wallentin L, Siegbahn A. Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy. J Am Med Assoc. 2001;286:2107–13.
18. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation. 2000;101:1767–72.
19. Harris TB, Ferrucci L, Tracy RP, Corti MC, Wacholder S, Ettinger Jr WH, et al. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med. 1999;106:506–12.
20. Volpato S, Guralnik JM, Ferrucci L, Balfour J, Chaves P, Fried LP, et al. Cardiovascular disease, interleukin-6, and risk of mortality in older women: the women’s health and aging study. Circulation. 2001;103:947–53.
21. Huber SA, Sakkinen P, Conze D, Hardin N, Tracy R. Interleukin-6 exacerbates early atherosclerosis in mice. Arterioscler Thromb Vasc Biol. 1999;19:2364–7.
22. Mallat Z, Corbaz A, Scoazec A, Graber P, Alouani S, Esposito B, et al. Interleukin-18/interleukin-18 binding protein signaling modulates atherosclerotic lesion development and stability. Circ Res. 2001;89:e41–5.
23. Elhage R, Jawien J, Rudling M, Ljunggren HG, Takeda K, Akira S, et al. Reduced atherosclerosis in interleukin-18 deficient apolipoprotein E-knockout mice. Cardiovasc Res. 2003;59:234–40.
24. Whitman SC, Ravisankar P, Daugherty A. Interleukin-18 enhances atherosclerosis in apolipoprotein E-/- mice through release of interferon-γ. Circ Res. 2002;90:e34–8.
25. Tenger C, Sundborger A, Jawien J, Zhou X. IL-18 accelerates atherosclerosis accompanied by elevation of IFN-γ and CXCL16 expression independently of T cells. Arterioscler Thromb Vasc Biol. 2005;25:791–6.
26. Okamura H, Tsutsi H, Komatsu T, Yutsudo M, Hakura A, Tanimoto T, et al. Cloning of a new cytokine that induces IFN- γ production by T cells. Nature. 1995;378:88–91.
27. Gerdes N, Sukhova GK, Libby P, Reynolds RS, Young JL, Schonbeck U. Expression of interleukin (IL)-18 and functional IL-18 receptor on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for atherogenesis. J Exp Med. 2002;195:245–57.
28. Ishida Y, Migita K, Izumi Y, Nakao K, Ida H, Kawakami A, et al. The role of IL-18 in the modulation of matrix metalloproteinases and migration of human natural killer (NK) cells. FEBS Lett. 2004;569:156–60.
29. Blankenberg S, Tiret L, Bickel C, Peetz D, Cambien F, Meyer J, et al. Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation. 2002;106:24–30.
30. Blankenberg S, Luc G, Ducimetiere P, Arveiler D, Ferrieres J, Amouyel P, et al. Interleukin-18 and the risk of coronary heart disease in European men: the Prospective Epidemiological Study of Myocardial Infarction (PRIME). Circulation. 2003;108:2453–9.
31. Koenig W, Khuseyinova N, Baumert J, Thorand B, Loewel H Chambless L, Meisinger C, Schneider A, Martin S, Kolb H, Herder C. Increased concentrations of C-reactive protein and interleukin-6 but not interleukin-18 are independently associated with incident coronary events in middle-aged men and women. Results from the MONICA/KORA Augsburg case-cohort study, 1984–2002. Arterioscler Thromb Vasc Biol. 2006;26(12):2745–51.
32. Tiret L, Godefroy T, Lubos E, Nicaud V, Tregouet DA, Barbaux S, et al. Genetic analysis of the interleukin-18 system highlights the role of the interleukin-18 gene in cardiovascular disease. Circulation. 2005;112:643–50.
33. Hurt-Camejo E, Camejo G, Peilot H, Oorni K, Kovanen P. Phospholipase A(2) in vascular disease. Circ Res. 2001;89:298–304.
34. Anthonsen MW, Stengel D, Hourton D, Ninio E, Johansen B. Mildly oxidized LDL induces expression of group IIa secretory phospholipase A(2) in human monocyte-derived macrophages. Arterioscler Thromb Vasc Biol. 2000;20:1276–82.
35. Sartipy P, Camejo G, Svensson L, Hurt-Camejo E. Phospholipase A(2) modification of low density lipoproteins forms small high density particles with increased affinity for proteoglycans and glycosaminoglycans. J Biol Chem. 1999;274:25913–20.
36. Leitinger N, Watson AD, Hama SY, Ivandic B, Qiao JH, Huber J, et al. Role of group II secretory phospholipase A2 in atherosclerosis: 2. Potential involvement of biologically active oxidized phospholipids. Arterioscler Thromb Vasc Biol. 1999;19:1291–8.
37. Boekholdt SM, Keller TT, Wareham NJ, Luben R, Bingham SA, Day NE, et al. Serum levels of type II secretory phospholipase A2 and the risk of future coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study. Arterioscler Thromb Vasc Biol. 2005;25:839–46.
38. 2) predict coronary events in patients with coronary artery disease. Circulation. 1999;100:1280–4.
39. 2 in patients with unstable angina pectoris. Am J Cardiol. 2000;86:718–22.
40. Mallat Z, Steg PG, Benessiano J, Tanguy ML, Fox KA, Collet JP, et al. Circulating secretory phospholipase A2 activity predicts recurrent events in patients with severe acute coronary syndromes. J Am Coll Cardiol. 2005;46:1249–57.
41. Nicholls SJ, Kastelein JJ, Schwartz GG, Bash D, Rosenson RS, Cavender MA, et al. Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial. JAMA. 2014;311(3):252–62.
42. Zalewski A, Macphee C. Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target. Arterioscler Thromb Vasc Biol. 2005;25:923–31.
43. 2, platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease. Atherosclerosis. 2000;150:413–9.
44. 2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. Biochem J. 1999;338:479–87.
45. 2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med. 2000;343:1148–55.
46. 2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2004;109:837–42.
47. 2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany. Circulation. 2004;110:1903–8.
48. 2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) Trial. Circulation. 2006;113:1745–52.
49. STABILITY Investigators, White HD, Held C, Stewart R, Tarka E, Brown R, et al. Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med. 2014;370(18):1702–11.
50. Mullard A. GSK’s darapladib failures dim hopes for anti-inflammatory heart drugs. Nat Rev Drug Discov. 2014;13(7):481–2.
51. Bunn RC, Fowlkes JL. Insulin-like growth factor binding protein proteolysis. Trends Endocrinol Metab. 2003;14:176–81.
52. Sangiorgi G, Mauriello A, Bonanno E, Oxvig C, Conover CA, Christiansen M, et al. Pregnancy-associated plasma protein-a is markedly expressed by monocyte-macrophage cells in vulnerable and ruptured carotid atherosclerotic plaques: a link between inflammation and cerebrovascular events. J Am Coll Cardiol. 2006;47:2201–11.
53. Bayes-Genis A, Conover CA, Overgaard MT, Bailey KR, Christiansen M, Holmes Jr DR, et al. Pregnancy-associated plasma protein A as a marker of acute coronary syndromes. N Engl J Med. 2001;345:1022–9.
54. Lund J, Qin QP, Ilva T, Pettersson K, Voipio-Pulkki LM, Porela P, et al. Circulating pregnancy-associated plasma protein a predicts outcome in patients with acute coronary syndrome but no troponin I elevation. Circulation. 2003;108:1924–6.
55. Heeschen C, Dimmeler S, Hamm CW, Fichtlscherer S, Simoons ML, Zeiher AM, et al. Pregnancy-associated plasma protein-A levels in patients with acute coronary syndromes: comparison with markers of systemic inflammation, platelet activation, and myocardial necrosis. J Am Coll Cardiol. 2005;45:229–37.
56. Lund J, Qin QP, Ilva T, Nikus K, Eskola M, Porela P, et al. Pregnancy-associated plasma protein A: a biomarker in acute ST-elevation myocardial infarction (STEMI). Ann Med. 2006;38:221–8.
57. Cosin-Sales J, Christiansen M, Kaminski P, Oxvig C, Overgaard MT, Cole D, et al. Pregnancy-associated plasma protein A and its endogenous inhibitor, the proform of eosinophil major basic protein (proMBP), are related to complex stenosis morphology in patients with stable angina pectoris. Circulation. 2004;109:1724–8.
58. Elesber AA, Conover CA, Denktas AE, Lennon RJ, Holmes Jr DR, Overgaard MT, et al. Prognostic value of circulating pregnancy-associated plasma protein levels in patients with chronic stable angina. Eur Heart J. 2006;27:1678–84.
59. Conti E, Andreotti F, Zuppi C. Pregnancy-associated plasma protein a as predictor of outcome in patients with suspected acute coronary syndromes. Circulation. 2004;109:e211–2.
60. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res. 2002;90:251–62.
61. Newby AC. Metalloproteinases and vulnerable atherosclerotic plaques. Trends Cardiovasc Med. 2007;17(8):253–8.
62. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest. 1994;94:2493–503.
63. Inokubo Y, Hanada H, Ishizaka H, Fukushi T, Kamada T, Okumura K. Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome. Am Heart J. 2001;141:211–7.
64. Kai H, Ikeda H, Yasukawa H, Kai M, Seki Y, Kuwahara F, et al. Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol. 1998;32:368–72.
65. Eckart RE, Uyehara CF, Shry EA, Furgerson JL, Krasuski RA. Matrix metalloproteinases in patients with myocardial infarction and percutaneous revascularization. J Interv Cardiol. 2004;17:27–31.
66. Blankenberg S, Rupprecht HJ, Poirier O, Bickel C, Smieja M, Hafner G, et al. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation. 2003;107:1579–85.
67. Lubos E, Schnabel R, Rupprecht HJ, Bickel C, Messow CM, Prigge S, et al. Prognostic value of tissue inhibitor of metalloproteinase-1 for cardiovascular death among patients with cardiovascular disease: results from the AtheroGene study. Eur Heart J. 2006;27:150–6.
68. Cavusoglu E, Ruwende C, Chopra V, Yanamadala S, Eng C, Clark LT, et al. Tissue inhibitor of metalloproteinase-1 (TIMP-1) is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction. Am Heart J. 2006;151:1101.e1–8.
69. Nicholls SJ, Hazen SL. Myeloperoxidase and cardiovascular disease. Arterioscler Thromb Vasc Biol. 2005;25:1102–11.
70. Eiserich JP, Baldus S, Brennan ML, Ma W, Zhang C, Tousson A, et al. Myeloperoxidase, a leukocyte-derived vascular NO oxidase. Science. 2002;296:2391–4.
71. Fu X, Kassim SY, Parks WC, Heinecke JW. Hypochlorous acid oxygenates the cysteine switch domain of pro-matrilysin (MMP-7). A mechanism for matrix metalloproteinase activation and atherosclerotic plaque rupture by myeloperoxidase. J Biol Chem. 2001;276:41279–87.
72. Shabani F, McNeil J, Tippett L. The oxidative inactivation of tissue inhibitor of metalloproteinase-1 (TIMP-1) by hypochlorous acid (HOCl) is suppressed by anti-rheumatic drugs. Free Radic Res. 1998;28:115–23.
73. Karakas M, Koenig W. Myeloperoxidase production by macrophage and risk of atherosclerosis. Curr Atheroscler Rep. 2012;14(3):277–83.
74. Shah PK. Jekyll and Hyde of HDL: a lipoprotein with a split personality. Eur Heart J. 2013;34(46):3531–4.
75. Huang Y, DiDonato JA, Levison BS, Schmitt D, Li L, Wu Y, et al. An abundant dysfunctional apolipoprotein A1 in human atheroma. Nat Med. 2014;20(2):193–203. An interesting study highlighting the concept of dysfunctional HDL and its potential prognostic role.
76. DiDonato JA, Aulak K, Huang Y, Wagner M, Gerstenecker G, Topbas C, et al. Site-specific nitration of apolipoprotein A-I at tyrosine 166 is both abundant within human atherosclerotic plaque and dysfunctional. J Biol Chem. 2014;289(15):10276–92.
77. Khurana R, Moons L, Shafi S, Luttun A, Collen D, Martin JF, et al. Placental growth factor promotes atherosclerotic intimal thickening and macrophage accumulation. Circulation. 2005;111:2828–36.
78. Iyer S, Acharya KR. Role of placenta growth factor in cardiovascular health. Trends Cardiovasc Med. 2002;12:128–34.
79. Heeschen C, Dimmeler S, Fichtlscherer S, Hamm CW, Berger J, Simoons ML, et al. Prognostic value of placental growth factor in patients with acute chest pain. J Am Med Assoc. 2004;291:435–41.
80. Lenderink T, Heeschen C, Fichtlscherer S, Dimmeler S, Hamm CW, Zeiher AM, et al. Elevated placental growth factor levels are associated with adverse outcomes at four-year follow-up in patients with acute coronary syndromes. J Am Coll Cardiol. 2006;47:307–11.
81. Namiki M, Kawashima S, Yamashita T, Ozaki M, Hirase T, Ishida T, et al. Local overexpression of monocyte chemoattractant protein-1 at vessel wall induces infiltration of macrophages and formation of atherosclerotic lesion: synergism with hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2002;22:115–20.
82. Inoue S, Egashira K, Ni W, Kitamoto S, Usui M, Otani K, et al. Anti-monocyte chemoattractant protein-1 gene therapy limits progression, and destabilization of established atherosclerosis in apolipoprotein E-knockout mice. Circulation. 2002;106:2700–6.
83. Herder C, Baumert J, Thorand B, Martin S, Lowel H, Kolb H, et al. Chemokines and incident coronary heart disease: results from the MONICA/KORA Augsburg case-cohort study, 1984–2002. Arterioscler Thromb Vasc Biol. 2006;26:2147–52.
84. Jessup W, Kritharides L, Stocker R. Lipid oxidation in atherogenesis: an overview. Biochem Soc Trans. 2004;32:134–8.
85. Meisinger C, Baumert J, Khuseyinova N, Loewel H, Koenig W. Plasma oxidized low-density lipoprotein, a strong predictor for acute coronary heart disease events in apparently healthy, middle-aged men from the general population. Circulation. 2005;112:651–7.
86. Tang WH, Wang Z, Levison BS, Koeth RA, Britt EB, Fu X, et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med. 2013;368(17):1575–84.
87. Wang Z, Klipfell E, Bennett BJ, Koeth R, Levison BS, Dugar B, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature. 2011;472(7341):57–63.
88. Hong SN1, Gona P, Fontes JD, Oyama N, Chan RH, Kenchaiah S, et al. Atherosclerotic biomarkers and aortic atherosclerosis by cardiovascular magnetic resonance imaging in the Framingham Heart Study. J Am Heart Assoc. 2013;2(6):e000307. doi:10.1161/JAHA.113.000307.
89. Shah PK. Screening asymptomatic subjects for subclinical atherosclerosis: can we, does it matter, and should we? J Am Coll Cardiol. 2010;56(2):98–105.